If you are:
Not Recommended: USE CONTRACEPTION DURING TREATMENT AND FOR 2 WEEKS AFTER; MAY CAUSE FETAL HARM
Absolute Contraindication: INSUFFICIENT HUMAN DATA AVAIL; POTENTIAL FOR SERIOUS ADVERSE EFFECTS
Giving Sorafenib tablet to a child under 12:
management or monitoring precaution: Not studied in pediatrics. No safety and efficacy. Potential risk of bone and bone marrow abnormalities.